New combo therapy aims to tame rare lymphoma without heavy side effects
NCT ID NCT07380984
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with early-stage nasal-type NK/T-cell lymphoma who have not had treatment before. It tests a personalized approach using a PD-1 antibody (a type of immunotherapy) combined with radiation therapy. The goal is to improve disease control while reducing side effects. About 47 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized lymphoma therapy: could lower radiation be enough?
- New drug duo shows promise for rare blood cancer
- AI model aims to predict lymphoma treatment success
- Supercharged donor cells take on lymphoma in early trial
- Experimental combo aims to boost stem cell transplant for rare blood cancers
- New drug cocktail aims to tackle tough lymphoma